Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease

Abstract Systemic sclerosis (SSc) is a severe multi-organ disease with interstitial lung disease (ILD) being the major cause of death. While targeted therapies are emerging, biomarkers for sub-stratifying patients based on individual profiles are lacking. Herein, we investigated how levels of serum...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	C. Meier, K. Freiburghaus, C. Bovet, J. Schniering, Y. Allanore, O. Distler, C. Nakas, B. Maurer
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4f13a07c3c2549ea99406944b37d68ba
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4f13a07c3c2549ea99406944b37d68ba
record_format	dspace
spelling	oai:doaj.org-article:4f13a07c3c2549ea99406944b37d68ba2021-12-02T13:34:00ZSerum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease10.1038/s41598-020-78951-62045-2322https://doaj.org/article/4f13a07c3c2549ea99406944b37d68ba2020-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-78951-6https://doaj.org/toc/2045-2322Abstract Systemic sclerosis (SSc) is a severe multi-organ disease with interstitial lung disease (ILD) being the major cause of death. While targeted therapies are emerging, biomarkers for sub-stratifying patients based on individual profiles are lacking. Herein, we investigated how levels of serum metabolites correlated with different stages of SSc and SSc-ILD. Serum samples of patients with SSc without ILD, stable and progressive SSc-ILD as well as of healthy controls (HC) were analysed using liquid targeted tandem mass spectrometry. The best discriminating profile consisted of 4 amino acids (AA) and 3 purine metabolites. l-tyrosine, l-tryptophan, and 1-methyl-adenosine distinguished HC from SSc patients. l-leucine, l-isoleucine, xanthosine, and adenosine monophosphate differentiated between progressing and stable SSc-ILD. In SSc-ILD, both, l-leucine and xanthosine negatively correlated with changes in FVC% predicted. Additionally, xanthosine was negatively correlated with changes in DLco% predicted and positively with the prognostic GAP index. Validation of l-leucine and l-isoleucine by an enzymatic assay confirmed both the sub-stratification of SSc-ILD patients and correlation with lung function and prognosis score. Serum metabolites may have potential as biomarkers for discriminating SSc patients based on the presence and severity of ILD. Confirmation in larger cohorts will be needed to appreciate their value for routine clinical care.C. MeierK. FreiburghausC. BovetJ. SchnieringY. AllanoreO. DistlerC. NakasB. MaurerNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q C. Meier K. Freiburghaus C. Bovet J. Schniering Y. Allanore O. Distler C. Nakas B. Maurer Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
description	Abstract Systemic sclerosis (SSc) is a severe multi-organ disease with interstitial lung disease (ILD) being the major cause of death. While targeted therapies are emerging, biomarkers for sub-stratifying patients based on individual profiles are lacking. Herein, we investigated how levels of serum metabolites correlated with different stages of SSc and SSc-ILD. Serum samples of patients with SSc without ILD, stable and progressive SSc-ILD as well as of healthy controls (HC) were analysed using liquid targeted tandem mass spectrometry. The best discriminating profile consisted of 4 amino acids (AA) and 3 purine metabolites. l-tyrosine, l-tryptophan, and 1-methyl-adenosine distinguished HC from SSc patients. l-leucine, l-isoleucine, xanthosine, and adenosine monophosphate differentiated between progressing and stable SSc-ILD. In SSc-ILD, both, l-leucine and xanthosine negatively correlated with changes in FVC% predicted. Additionally, xanthosine was negatively correlated with changes in DLco% predicted and positively with the prognostic GAP index. Validation of l-leucine and l-isoleucine by an enzymatic assay confirmed both the sub-stratification of SSc-ILD patients and correlation with lung function and prognosis score. Serum metabolites may have potential as biomarkers for discriminating SSc patients based on the presence and severity of ILD. Confirmation in larger cohorts will be needed to appreciate their value for routine clinical care.
format	article
author	C. Meier K. Freiburghaus C. Bovet J. Schniering Y. Allanore O. Distler C. Nakas B. Maurer
author_facet	C. Meier K. Freiburghaus C. Bovet J. Schniering Y. Allanore O. Distler C. Nakas B. Maurer
author_sort	C. Meier
title	Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
title_short	Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
title_full	Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
title_fullStr	Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
title_full_unstemmed	Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
title_sort	serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/4f13a07c3c2549ea99406944b37d68ba
work_keys_str_mv	AT cmeier serummetabolitesasbiomarkersinsystemicsclerosisassociatedinterstitiallungdisease AT kfreiburghaus serummetabolitesasbiomarkersinsystemicsclerosisassociatedinterstitiallungdisease AT cbovet serummetabolitesasbiomarkersinsystemicsclerosisassociatedinterstitiallungdisease AT jschniering serummetabolitesasbiomarkersinsystemicsclerosisassociatedinterstitiallungdisease AT yallanore serummetabolitesasbiomarkersinsystemicsclerosisassociatedinterstitiallungdisease AT odistler serummetabolitesasbiomarkersinsystemicsclerosisassociatedinterstitiallungdisease AT cnakas serummetabolitesasbiomarkersinsystemicsclerosisassociatedinterstitiallungdisease AT bmaurer serummetabolitesasbiomarkersinsystemicsclerosisassociatedinterstitiallungdisease
_version_	1718392793250922496

Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease

Ejemplares similares